breast cancer cell model
Recently Published Documents


TOTAL DOCUMENTS

23
(FIVE YEARS 6)

H-INDEX

6
(FIVE YEARS 1)

Metabolomics ◽  
2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Lindsey Rasmussen ◽  
Zachary Foulks ◽  
Casey Burton ◽  
Honglan Shi

Cancers ◽  
2021 ◽  
Vol 13 (20) ◽  
pp. 5130
Author(s):  
Taylor E. Escher ◽  
Prasad Dandawate ◽  
Afreen Sayed ◽  
Christy R. Hagan ◽  
Shrikant Anant ◽  
...  

Aromatase inhibitors (AIs) reduce estrogen levels up to 98% as the standard practice to treat postmenopausal women with estrogen receptor-positive (ER+) breast cancer. However, approximately 30% of ER+ breast cancers develop resistance to treatment. Enhanced interferon-alpha (IFNα) signaling is upregulated in breast cancers resistant to AIs, which drives expression of a key regulator of survival, interferon-induced transmembrane protein 1 (IFITM1). However, how upregulated IFNα signaling mediates AI resistance is unknown. In this study, we utilized MCF-7:5C cells, a breast cancer cell model of AI resistance, and demonstrate that these cells exhibit enhanced IFNα signaling and ligand-independent activation of the estrogen receptor (ERα). Experiments demonstrated that STAT1, the mediator of intracellular signaling for IFNα, can interact directly with ERα. Notably, inhibition of IFNα signaling significantly reduced ERα protein expression and ER-regulated genes. In addition, loss of ERα suppressed IFITM1 expression, which was associated with cell death. Notably, chromatin immunoprecipitation experiments validated that both ERα and STAT1 associate with ERE sequences in the IFITM1 promoter. Overall, hyperactivation of IFNα signaling enhances ligand-independent activation of ERα, which promotes ER-regulated, and interferon stimulated gene expression to promote survival in AI-resistant breast cancer cells.


2021 ◽  
Vol 11 (2) ◽  
pp. 326-332
Author(s):  
Le Ma ◽  
Zhenyu Liu ◽  
Zhimin Fan

Breast cancer is one of the most prevailing cancers in females, while the cancerous heterogeneity hinders its early diagnosis and subsequent therapy. miR-143-3p is a critical mediator in malignancy development and tumorigenesis as a tumor suppressor. Its role in various tumor entities has been investigated, such as colon cancer and breast cancer. Using MCF-7 breast cancer cell model, we planned to explore the underlying mechanisms of miR-143/KLF-5 axis in retarding breast cancer cells growth. Bioinformatics analysis searched the target KLF5 of miR-143, and the miR-143-targeted mimic and inhibitor were employed to detect the changes of KLF5. After transfection of mimic miR-143, the CCK-8 reagent assessed cell proliferation. Based on optimal stimulation time, miR-143 stimulation model was established, followed by determining expression of KLF5, EGFR and PCNA via western blot and qPCR. Eventually, siRNA-KLF5 was applied to silencing KLF5 level to evaluate its role in MCF-7 cells. The transcription and translation levels of KLF5 were diminished in miR-143-mimic transfected MCF-7 cells, while enhanced in miR-143-inhibitor transfected MCF-7 cells. When MCF-7 cells were transfected with miR-143-mimic at different time points, 48 hours was found to be the optimal transfection time, with reduced transcription and translation levels of KLF5, EGFR and PCNA. The transcription and translation levels of PNCA and EGFR were declined after silencing KLF5 by siRNA. miR-143/KLF5 axis could retard the proliferation of MCF-7 breast cancer cells.


2021 ◽  
Vol 37 (2) ◽  
pp. 76-80
Author(s):  
A.A. Poloznikov

A method has been developed for assessing the proportion of lysed MDA-MB-231 cells cultured in the multi-organ human-on-a-chip model based on the determination of the hsa-miR-222-3p and hsa-miR-99b-5p microRNA levels in the culture medium. The threshold levels of microRNA expression were calculated, which made it possible to estimate the proportion of lysed cells with an accuracy of 25%. microRNA, breast cancer, cell model This work was supported by the Ministry of Education and Science of the Russian Federation (grant RFMEFI61618X0092).


2017 ◽  
Vol 14 (2) ◽  
pp. 172-178
Author(s):  
Nuno Almeida ◽  
Lara Ribeiro ◽  
João G. Costa ◽  
Patricia Rijo ◽  
M. Eduarda Araújo ◽  
...  

Gene ◽  
2017 ◽  
Vol 627 ◽  
pp. 408-411 ◽  
Author(s):  
Besra Özmen Yelken ◽  
Tuğçe Balcı ◽  
Sunde Yılmaz Süslüer ◽  
Çağla Kayabaşı ◽  
Çığır Biray Avcı ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document